Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 2.730 | 2.730 | 0.000 |
Shares | 97.210 | 97.210 | 0.000 |
Other | 0.060 | 0.060 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 26.563 | 18.747 |
Price to Book | 7.776 | 3.221 |
Price to Sales | 5.829 | 2.271 |
Price to Cash Flow | 20.714 | 12.615 |
Dividend Yield | 1.071 | 1.998 |
5 Years Earnings Growth | 13.481 | 11.561 |
Name | Net % | Category Average |
---|---|---|
Technology | 45.710 | 20.190 |
Healthcare | 36.290 | 14.129 |
Communication Services | 18.000 | 8.865 |
Number of long holdings: 29
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Apple | US0378331005 | 9.05 | 258.20 | +1.15% | |
NVIDIA | US67066G1040 | 8.36 | 140.22 | +0.39% | |
Microsoft | US5949181045 | 8.33 | 439.33 | +0.94% | |
Alphabet A | US02079K3059 | 7.96 | 196.11 | +0.76% | |
Meta Platforms | US30303M1027 | 5.57 | 607.75 | +1.32% | |
Roche Holding Participation | CH0012032048 | 5.41 | 251.00 | +1.46% | |
Novartis | CH0012005267 | 4.47 | 87.68 | +1.11% | |
UnitedHealth | US91324P1021 | 4.46 | 506.10 | -0.05% | |
Thermo Fisher Scientific | US8835561023 | 3.59 | 528.98 | +0.70% | |
Eli Lilly | US5324571083 | 3.51 | 795.67 | -0.08% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CIBC Nasdaq Index | 3.89B | 30.73 | 11.84 | 18.92 | ||
CIBC Nasdaq Index Premium Class | 3.89B | 31.68 | 12.76 | 19.95 | ||
CIBC US Broad Market Index | 2.64B | 33.57 | 12.09 | 13.44 | ||
CIBC US Broad Market Index Premium | 2.64B | 34.45 | 12.92 | 14.32 | ||
CIBC Managed Growth Portfolio T8 | 38.62M | 15.38 | 5.59 | 6.68 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review